Company Overview and News

Cassini Resources receives new data to confirm zinc target

Cassini Resources Ltd (ASX:CZI) has received new data supporting its interpretation of sedimentary zinc mineralisation at the West Arunta Project in Western Australia.

Top 6 Cobalt Junior Developer Miners To Boom By 2021/2022

2018-05-17 seekingalpha
Six cobalt junior developers can each produce ~5,000 tonnes pa of cobalt by 2021/22. These companies each have the potential to be worth ~AUD 3b if cobalt prices remain strong.

Cassini Resources has "solid development project" and "significant" exploration targets

Cassini Resources Ltd (ASX:CZI) managing director Richard Bevan tells Proactive Investors that the base and precious metals explorer and developer now has, "a really solid development project with a great portfolio of exploration assets."

Cassini Resources identifies new nickel copper cobalt targets

Cassini Resources Ltd (ASX:CZI) has received results from an airborne electromagnetic (EM) survey at the Tarawindah Brook Project, 130 kilometres from Perth in Western Australia.

Cobalt Miners News For The Month Of April 2018

2018-04-25 seekingalpha
Cobalt miner news - South Korea's LG Chem to set up battery material JVs with China's Zhejiang Huayou Cobalt.

Cassini Resources ramps up pre-feasibility study work at West Musgrave

Cassini Resources Ltd (ASX:CZI) has commenced a significant field program at its West Musgrave nickel-copper project in Western Australia.

A Look At The Junior Cobalt Miners In Early 2018

2018-04-17 seekingalpha
This article first appeared on Trend Investing on February 16, therefore all data is as of that date.

Cassini Resources works towards PFS with Oz Minerals as its joint venture partner

Cassini Resources Ltd (ASX:CZI) has transformed over the years from a single asset group to a company with a broad range of projects and importantly exposure to precious and base metals.

Cassini Resources commences airborne survey for zinc at West Arunta

Cassini Resources Ltd (ASX:CZI) has commenced a high-resolution, airborne electromagnetic (AEM) survey at its West Arunta Project in Western Australia.

Cobalt Miners News For The Month Of March 2018

2018-03-25 seekingalpha
Cobalt spot price news - Spot prices rise 18.7% in the past month as inventory falls. The cobalt spot price is now over USD 40/lb, and approaching USD 100,000/tonne.

Australia Mines Offers Nickel-Cobalt Exposure With Three Promising Projects In Australia

2018-03-21 seekingalpha
The Sconi resource estimate has 54,500 tonnes of contained cobalt with exploration upside. The Sconi project has recently secured 100% cobalt and nickel off-take.

Time To Buy Some Nickel Miners

2018-03-16 seekingalpha
The nickel miner fundamentals are steadily improving, with demand likely to strengthen post 2020 due to the EV boom.

Time To Buy Some Cobalt Miners

2018-03-09 seekingalpha
The cobalt miners strangely fell in January following the lithium miners despite very strong cobalt price gains.

Woomera Mining expects to complete IPO by listing on Monday

Woomera Mining Limited (ASX:WML) expects to list on the ASX on Monday 5 March through a backdoor IPO via AusROC Metals Limited (ASX:ARK).

Cobalt Miners News For The Month Of February 2018

2018-02-23 seekingalpha
Cobalt market news - the DRC to hike taxes on Congo cobalt miners. ERG says "cobalt boom ‘guaranteed’ for 7-10 years."

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...